Literature DB >> 17245013

Lymphoplasmacyte-rich meningioma with atypical invasive nature.

Hidenori Nohara1, Kazuhide Furuya, Nobutaka Kawahara, Akira Iijima, Kyoko Yako, Junji Shibahara, Takaaki Kirino.   

Abstract

A 12-year-old boy presented with a lymphoplasmacyte-rich (LPR) meningioma in the posterior fossa. The tumor was subtotally removed. Histological examination showed the tumor had invaded the normal brain tissue despite its benign grade in the World Health Organization classification. The Ki-67 staining index using MIB-1 monoclonal antibody was relatively high. (18)F-2-fluoro-2-deoxy-D-glucose positron emission tomography revealed high uptake in the tumor. These findings indicate the atypical nature of LPR meningioma.

Entities:  

Mesh:

Year:  2007        PMID: 17245013     DOI: 10.2176/nmc.47.32

Source DB:  PubMed          Journal:  Neurol Med Chir (Tokyo)        ISSN: 0470-8105            Impact factor:   1.742


  4 in total

1.  Lymphoplasmacyte-rich meningioma: our experience with 19 cases and a systematic literature review.

Authors:  Hong-Da Zhu; Qing Xie; Ye Gong; Ying Mao; Ping Zhong; Feng-Ping Hang; Hong Chen; Ming-Zhe Zheng; Hai-Liang Tang; Dai-Jun Wang; Xian-Cheng Chen; Liang-Fu Zhou
Journal:  Int J Clin Exp Med       Date:  2013-08-01

2.  Lymphoplasmacyte-rich meningioma: A rare histologic variant of benign meningioma with atypical bone invasion.

Authors:  Gonçalo Borges de Almeida; Gonçalo Januário
Journal:  Radiol Case Rep       Date:  2022-01-15

3.  Lymphoplasmacyte-rich meningioma with hematologic signs and PD-L1 over-expression.

Authors:  Gabriele Gaggero; Michela Campora; Davide Taietti; Giannamaria Cerruti; Enrico Lo Bue; Monica Truffelli; Marco Ceraudo; Pietro Fiaschi
Journal:  Autops Case Rep       Date:  2022-08-12

4.  Lymphoplasmacyte-rich meningioma with invasion of bone: A case report and review of literature.

Authors:  Dhruba J Kurmi; Achal Sharma; R S Mittal; Shashi Singhvi
Journal:  Asian J Neurosurg       Date:  2016 Oct-Dec
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.